News

TCON is focused on the development and commercialization of new targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases. The agreement strengthens intellectual property estate around TRC102

The company intends to begin a Phase I trial in the second quarter of 2015 to evaluate the safety and tolerability of AGT-181 in adult patients with mucopolysaccharidosis

The FDA concluded that Perrigo’s products are therapeutically equivalent to Mallinckrodt’s Exalgo (hydromorphone HCI extended-release tablets) 8mg, 12mg and 16mg. According to the agency these products can be

CAP-1002 is being developed to treat advanced heart failure, including patients who were Class III or ambulatory Class IV with ejection fractions of 35% or below. A total

These standard chemotherapies include paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy. The approval was based on data from the pivotal

As part of the non-binding proposal, Perrigo shareholders would receive $205 in a combination of cash and Mylan stock for each Perrigo share. In a statement, Perrigo has

Designed to evaluate the safety and efficacy of ALX-0061, the trial is also aimed at obtaining parallel descriptive information concerning the efficacy and safety of administration of sc

The complete line of Bikini Ready’s women’s weight loss solutions includes Weight Loss Catalyst and Cleanse Cleanse nutritional supplements, as well as Yummy Nutrition Shakes. In 2014, Bikini

Tenofovir alafenamide fumarate (TAF) is a nucleotide reverse transcriptase inhibitor (NRTI) and a new prodrug of tenofovir. This is the company’s second NDA submitted to the FDA for